HLS Therapeutics Inc. (OTCMKTS:HLTRF) Stock Short Interest Jumps 1,746.0%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 1,846 shares, a growth of 1,746.0% from the October 15th total of 100 shares. Based on an average daily volume of 4,910 shares, the short-interest ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

HLS Therapeutics Price Performance

OTCMKTS:HLTRF opened at $3.20 on Wednesday. HLS Therapeutics has a one year low of $2.64 and a one year high of $3.70. The stock has a 50 day moving average price of $2.86 and a 200 day moving average price of $3.09.

HLS Therapeutics Company Profile

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution. The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.